KING PHARMACEUTICALS INC (KG) is a publicly traded company in the Unknown sector. Across all available filings, 24 corporate insiders have executed 286 transactions totaling $3.7M, demonstrating a bearish sentiment with -$3.5M in net insider flow. The most recent transaction on Sep 5, 2025 involved a transaction of 2,337 shares valued at $0.
No significant insider buying has been recorded for KG in the recent period.
No significant insider selling has been recorded for KG in the recent period.
Based on recent SEC filings, insider sentiment for KG is bearish with an Insider Alignment Score of 3/100 and a net flow of -$3.5M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at KING PHARMACEUTICALS INC (KG) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 24 insiders are actively trading KG stock, having executed 286 transactions in the past 90 days. The most active insider is Brian A. Markison (Executive), who has made 24 transactions totaling $4.4M.
Get notified when executives and directors at KG file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Sep 5, 2025 | Weissmann Jeffrey | Executive | Award | 2,337 | $N/A | $0 | |
| Sep 5, 2025 | Harold Nigro Steven | Executive | Award | 2,337 | $N/A | $0 | |
| Sep 5, 2025 | Cohen Erik | Executive | Award | 2,337 | $N/A | $0 | |
| Sep 5, 2025 | Brecher Joseph | Executive | Award | 2,337 | $N/A | $0 | |
| Sep 5, 2025 | Hotchkiss Michael | Executive | Award | 2,337 | $N/A | $0 | |
| Jan 31, 2011 | Squicciarino Joseph | Executive | Disposition | 74,740 | $N/A | $0 | |
| Jan 31, 2011 | Squicciarino Joseph | Executive | Tender | 347,687 | $N/A | $0 | |
| Jan 31, 2011 | G. Wood Ted | Executive | Tender | 59,460 | $N/A | $0 | |
| Jan 31, 2011 | L. Schaffer Derace | Executive | Tender | 10,000 | $N/A | $0 | |
| Jan 31, 2011 | Gregory Rooker D. | Executive | Tender | 53,145 | $N/A | $0 | |
| Jan 31, 2011 | Gregory Rooker D. | Executive | Tender | 1,350 | $N/A | $0 | |
| Jan 31, 2011 | Moyer Charles | Executive | Tender | 16,012 | $N/A | $0 | |
| Jan 31, 2011 | A. Markison Brian | Executive | Disposition | 200,760 | $N/A | $0 | |
| Jan 31, 2011 | A. Markison Brian | Executive | Tender | 547,360 | $N/A | $0 | |
| Jan 31, 2011 | D. Jordan Gregory | Executive | Tender | 41,679 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Payment(F) | 44 | $7.5M | 59.0% |
Sale(S) | 35 | $3.6M | 28.3% |
Award(A) | 129 | $1.3M | 10.3% |
Exercise(M) | 29 | $195.3K | 1.5% |
Purchase(P) | 2 | $105.7K | 0.8% |
Disposition(D) | 7 | $0 | 0.0% |
Tender(U) | 14 | $0 | 0.0% |
Gift(G) | 26 | $0 | 0.0% |
Insider selling pressure at KING PHARMACEUTICALS INC has increased, with 24 insiders executing 286 transactions across all time. Total sales of $3.6M significantly outpace purchases of $105.7K, resulting in a net outflow of $3.5M. This selling activity appears largely discretionary, which may warrant closer attention from investors.